CN107028948B - Purposes of the compound in the medicine for preparing treatment climacteric xerophthalmia - Google Patents
Purposes of the compound in the medicine for preparing treatment climacteric xerophthalmia Download PDFInfo
- Publication number
- CN107028948B CN107028948B CN201710204729.4A CN201710204729A CN107028948B CN 107028948 B CN107028948 B CN 107028948B CN 201710204729 A CN201710204729 A CN 201710204729A CN 107028948 B CN107028948 B CN 107028948B
- Authority
- CN
- China
- Prior art keywords
- medicine
- xerophthalmia
- group
- present
- climacteric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 238000011282 treatment Methods 0.000 title claims abstract description 20
- 208000005494 xerophthalmia Diseases 0.000 title claims abstract description 14
- 150000001875 compounds Chemical class 0.000 title claims description 9
- 239000003889 eye drop Substances 0.000 claims description 7
- 229940012356 eye drops Drugs 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract description 8
- 206010013774 Dry eye Diseases 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 210000000270 basal cell Anatomy 0.000 abstract description 6
- 210000004969 inflammatory cell Anatomy 0.000 abstract description 6
- 210000003560 epithelium corneal Anatomy 0.000 abstract description 4
- 239000003163 gonadal steroid hormone Substances 0.000 abstract description 4
- 230000008595 infiltration Effects 0.000 abstract description 4
- 238000001764 infiltration Methods 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- 108010019783 tear proteins Proteins 0.000 abstract description 4
- 239000003098 androgen Substances 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000028327 secretion Effects 0.000 abstract description 3
- 206010003694 Atrophy Diseases 0.000 abstract description 2
- 230000037444 atrophy Effects 0.000 abstract description 2
- 210000000744 eyelid Anatomy 0.000 abstract description 2
- 230000000762 glandular Effects 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 238000007086 side reaction Methods 0.000 abstract description 2
- 235000004252 protein component Nutrition 0.000 abstract 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000010445 Lactoferrin Human genes 0.000 description 5
- 108010063045 Lactoferrin Proteins 0.000 description 5
- 102000016943 Muramidase Human genes 0.000 description 5
- 108010014251 Muramidase Proteins 0.000 description 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 5
- 235000021242 lactoferrin Nutrition 0.000 description 5
- 229940078795 lactoferrin Drugs 0.000 description 5
- 239000004325 lysozyme Substances 0.000 description 5
- 229960000274 lysozyme Drugs 0.000 description 5
- 235000010335 lysozyme Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000004382 Amylase Substances 0.000 description 4
- 102000013142 Amylases Human genes 0.000 description 4
- 108010065511 Amylases Proteins 0.000 description 4
- 235000019418 amylase Nutrition 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960002143 fluorescein Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 238000009165 androgen replacement therapy Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- -1 cationic lipid Chemical class 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940020947 fluorescein sodium Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 206010023683 lagophthalmos Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000002577 ophthalmoscopy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition for treating climacteric xerophthalmia, the pharmaceutical composition has following innovative structure：Medicine of the present invention can obviously improve dry eyes SIT caused by climacteric sex hormone level declines and change Tear protein component, the inflammatory cell infiltration and the corneal epithelium basal cell atrophy that promote eyelid glandular secretion, effectively reduce androgen dysfunctional xerophthalmia, it is that one kind is safe and effective, method of administration is simple, side reaction is few, the medicine of the long-term use for the treatment of dry eyes of patient's energy, has extensive clinical practice and promotional value.
Description
Technical field
The present invention relates to field of medicaments, and specifically, the present invention relates to a kind of medicine group for treating climacteric xerophthalmia
Compound.
Background technology
Xerophthalmia is due to that the caused tear film of exception of the amount or matter of tear is unstable and eye surface is damaged, and be drastically influence
Patient's vision and life, and illness rate rises year by year.Eye is one of important target organ of sex hormone function, under sex hormone level
Drop, tear film are unstable, local inflammation reaction aggravates, and result in the formation of xerophthalmia.Done caused by declining for androgen levels
Eye disease patient, it is more with local symptomatic treatment at present, and androgen replacement therapy side effect is more, patient is not easily accepted by.Therefore, it is clinical
Finding a kind of alternative medicine becomes ophthalmology urgent problem.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition for treating climacteric xerophthalmia.
In order to realize the purpose of the present invention, the present invention provides a kind of pharmaceutical composition for treating climacteric xerophthalmia, institute
Stating pharmaceutical composition has formula：
Preferably, emulsion and eye drops can be made in described pharmaceutical composition.
It is highly preferred that the pharmaceutical composition of emulsion form can also include water and be dispersed in water non-polar phospholipid,
The mixture of the cationic lipid of non-polar oil, non-toxic emulsifying agent and imparting tear film net positive charge, it causes tear film quiet
Electric attraction is to anionic eye surface and adheres to thereon to suppress its evaporation.
It is highly preferred that the pharmaceutical composition can also include glycerine, mannitol, phosphate, nipalgin when eye drops is made
Propyl ester, butyl hydroxybenzoate and water.
The present invention also provides purposes of the compound in the medicine for preparing treatment climacteric xerophthalmia, the compound tool
There is having structure：
Preferably, emulsion and eye drops can be made in the compound.
Medicine of the present invention can obviously improve dry eyes SIT caused by climacteric sex hormone level declines and change tear egg
Bai Chengfen, the inflammatory cell infiltration and corneal epithelium base for promoting eyelid glandular secretion, effectively reducing androgen dysfunctional xerophthalmia
Floor cells atrophy, it is that one kind is safe and effective, method of administration is simple, side reaction is few, the medicine for the treatment dry eyes that patient can be long-term use of
Thing, there is extensive clinical practice and promotional value.
Brief description of the drawings
Fig. 1 is pretherapy and post-treatment each group confocal microscope result.
A. normal group；B. model group；C. medicine group of the present invention.
Embodiment
Therapeutic effect of the medicine of the present invention to climacteric xerophthalmia is described in detail below by embodiment.
The sign of 1 medicine of the present invention of experimental example
1H-NMR(CDCl3):δ0.85-1.03(m,4H),2.65-2.89(t,4H),3.56(s,2H),7.22 -7.26
(m,1H),7.36-7.61(m,6H),7.83-7.89(m,1H),8.69(s,1H)。
The effect of the drug therapy climacteric xerophthalmia of the present invention of experimental example 2
The preparation of medicine eye drops of the present invention：The medicine of embodiment 1, water are dissolved with distilled water:Drug quality ratio is 100:1,
Eye lubricant carboxymethyl cellulose is added, concentration control 1.5%, adds NaHCO3And KCl is as buffer system, concentration control
System is below 0.1%.Physicochemical property pH, osmotic pressure, proportion, surface tension, stickiness and infractive index are now detected, is adjusted afterwards
Whole medicine, eye lubricant, the content of buffer system, it is allowed to reach as far as possible：pH 7.3-7.8；Osmotic pressure：311-350mOsm；Than
Weight：It is approximately equal to 1；Surface tension：40-50dyn·cm-2；Stickiness：Slightly above water；Infractive index：1.336 standard.Finally plus
Enter preservative agent benzalkonium bromide, its concentration controls 0.005 weight %.
Animal packet and operation
New zealand white rabbit (at 2 monthly ages, be female, body weight 2.0-2.5kg).Slit-lamp microscope, funduscopy eye
Prosthomere and eyeground are without exception, basic Schimer's test (SIT) >=10 mm/5min.It is normal group to choose 10, remaining reference
(Hong Ying ovaries cut off gynaecology practical with relation [J] of menopausal syndrome China and obstetrics' magazine, 1996,12 (6) to document:
350.), by doe row bilateral oophorectomy.After operation 2 months, modeling success rabbit is randomly divided into：Model group, medicine of the present invention
Thing group, every group 10, be right eye.Eye drops, medicine group of the present invention do not drip medicine eye drops of the present invention for normal group and model group
0.01mL/kg.Continuous eye drip 2 months, 4 times a day.The preoperative U of muscle instillation penicillin pin 200,000, postoperative continuous 3d intramuscular injection are blue or green
The U of mycin pin 200,000, prevention infection.Before medication 1 week after (i.e. postoperative 2 months), medication, 2 weeks, January and 2 months enters to rabbit
Row SIT is checked, corneal fluorescein dyes (FL), tear protein measure and cornea scanning cofocal microscope.
SIT is detected and corneal fluorescein dyeing
SIT checks tear basal secretion situation, and method is to take the graduated test paper of 5mm × 35mm, one end reflexed 5mm, gently
Put down gently at the China and foreign countries 1/3 of conjunctival sac under tested eye, filter paper is taken out after 5mi n, measure wet length, be normal using >=10mm/5min.
Every group of animal checks that every group of animal each review time, place, brightness of illumination, humidity and temperature are identical by same people.Cornea
Fluorescent staining：1% fluorescein sodium eye drip is dripped by 1, it is twinkled, points-scoring system studies clinical dry eyes scoring with reference to National Eye
(Lemp M A.Report of the nationa l eye institute/industry workshop on clinical
trials in dry eyes[J]. CLAO.J.1995.21(4):221.), it is divided into 4 grades, 0 grade：Dye-free；1 grade：Seldom
Dissemination spot dyes；2 grades：Moderate spot dyes, and degree is between 1-3 levels；3 grades：Severe amalgamation spot dyes.
Tear protein determines
All ocular fluid samples draw the μ L non-irritating tears of lacrimal river about 20 under rabbit in 9 points to 11 points collections, capillary syring
Liquid, it is placed in 0.5mL EP pipes in -80 DEG C of refrigerators and preserves.Using bSA as standard, Brandford methods measure tear is total
Protein content.Amylase activity measurement bibliography (Chen Zhiyuan, Jie Ying, Yu Guangyan.Treatment
of severe keratoconjunctivitis sicca by parotid duct transposition after
tympanic neurectomy in rabbits[J].Invest Ophthalmol Vis Sci,2011,52(9):
6964.).Double-colored reading is analyzed in 405nm and 546nm using automatic biochemistry analyzer；Lactoferrin measure uses radio-immunity
Analytic approach：Take the μ L of ocular fluid samples 10, physiological saline 1:100 dilutions, lactoferrin content is calculated after making standard curve.Bacteriolyze
Enzyme content is determined using test tube turbidimetry, and lysozyme testing cassete, prepared by dyeing bacterium solution, lysozyme standard liquid is prepared and standard curve
The equal by specification of drafting carry out；Tear and dyeing bacterium solution are mixed, supernatant is taken after centrifugation, according to measure pipe and sample controls
Pipe absorbance difference, lysozyme content in sample is drawn after looking into standard curve.
Confocal microscope inspection
Using the crack scanning Laser Scanning Confocal Microscope inspections of Confoscan 4, operating procedure bibliography (Chen W, Li Z,
Hu J,etal.Corneal alternations induced by topi cal application of
benzalkonium chloride in rabbit[J].PLoSONE,20 11,6(10):e26103.)：Lagophthalmos table fiber crops to be checked
Afterwards, before rabbit head being fixed into microscope, immediately ahead of eyes fixation, examiner's moving lens makes confocal microscope thin in corneal epithelium
During born of the same parents, camera lens is slowly pushed ahead, holostrome scanning is carried out at central cornea, valuable image and video recording are selected after terminating
Deposit, and calculate corneal epithelium basal cell and inflammatory cell density.
Statistical method using GraphPad Prism4.00 statistical softwares carry out statistical procedures, measurement data with
Represent, enumeration data χ2Examine, inspection level is α=0.05；Each group before and after treatment and 2 groups between same time point mean
Compare and examined using One-way ANOVA student-t inspections and Dunnett.With P<0.05 is statistically significant as difference.
Every dry eyes Testing index evaluation result (mm) is compared between pretherapy and post-treatment each group
2 groups of model group, medicine group of the present invention SIT are compared before treatment, no significant difference；After treatment 2 months, the present invention
Medicine group SIT is improved in varying degrees (P before relatively treating<0.05) (P is substantially deteriorated before, model group SIT is relatively treated<0.05)；
Model group, each time point SIT of 2 groups of medicine group of the present invention are compared, the statistically significant (P of difference<0.05), as a result see the table below.
| Group | Before treatment | 1 week | 2 weeks | January | 2 months |
| Normal group | 8.14±3.00 | 8.15±2.97 | 8.12±2.95 | 8.10±3.03 | 8.07±2.91 |
| Model group | 4.52±2.14 | 3.76±2.45 | 3.51±1.65 | 3.30±2.04 | 2.88±1.90 |
| The present invention | 4.75±2.85 | 4.00±2.86 | 4.17±2.79 | 6.98±2.39 | 7.90±2.37 |
2 groups of model group, medicine group of the present invention fluorescent staining scorings are compared before treatment, no significant difference；Treatment 2
After month, medicine group fluorescent staining scoring of the present invention has before relatively treating declines (P in various degree<0.05), model group fluorescence
Significantly raised (p before the scoring of uniformly dyeing color is relatively treated<0.05)；2 weeks after 2 groups of model group, medicine group of the present invention treatments, January, 2 months it is glimmering
The scoring of light uniformly dyeing color is compared, the statistically significant (p of difference<0.05), as a result see the table below：
| Group | Before treatment | 1 week | 2 weeks | January | 2 months |
| Normal group | 1.72±1.21 | 1.77±1.30 | 1.70±1.13 | 1.68±1.26 | 1.65±1.20 |
| Model group | 4.76±1.05 | 5.21±1.15 | 5.55±1.40 | 6.76±2.10 | 6.87±2.83 |
| The present invention | 4.83±0.97 | 5.15±1.17 | 4.15±1.52 | 3.12±0.96 | 1.45±1.54 |
Each time point tear protein compares before and after medication
Model group, 2 groups of tear total protein concentrations of medicine group of the present invention, lactoferrin, lysozyme and amylase activity before treatment
Compare, no significant difference；It is model group, medicine group tear total protein concentration of the present invention, lactoferrin, molten after treatment 2 months
Bacterium enzyme and the amylase activity statistically significant (P of difference compared with pre-treatment<0.05)；Model group, 2 groups of medicine group of the present invention are each
Time point tear total protein concentration, lactoferrin, lysozyme and amylase activity are compared, the statistically significant (P of difference<
0.05), as a result see the table below：
Pretherapy and post-treatment each group confocal microscope result
Fig. 1 is shown：Normal cornea epithelium basal cell is shown as brightness cell body, narrow cell boundaries.After modeling, cornea
Epithelium basal cell volume-diminished, it is seen that have the inflammatory cell infiltration in light sample.By drug-treated this hair of 2 months of the present invention
Bright medicine group is in the inflammatory cell infiltration of the visible only a few of epithelium basalis, but density is slightly compared with normal doe basal cell
Reduce.Model group epithelium basalis it is visible to have substantial amounts of be in light sample inflammatory cell, epithelium basal cell density substantially increases.
Claims (2)
1. purposes of the compound in the medicine for preparing treatment climacteric xerophthalmia, it is characterised in that the compound has
Having structure：
。
2. purposes according to claim 1, it is characterised in that emulsion and eye drops is made in the compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710204729.4A CN107028948B (en) | 2017-03-30 | 2017-03-30 | Purposes of the compound in the medicine for preparing treatment climacteric xerophthalmia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710204729.4A CN107028948B (en) | 2017-03-30 | 2017-03-30 | Purposes of the compound in the medicine for preparing treatment climacteric xerophthalmia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107028948A CN107028948A (en) | 2017-08-11 |
| CN107028948B true CN107028948B (en) | 2018-01-09 |
Family
ID=59534230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710204729.4A Expired - Fee Related CN107028948B (en) | 2017-03-30 | 2017-03-30 | Purposes of the compound in the medicine for preparing treatment climacteric xerophthalmia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107028948B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105229006A (en) * | 2013-03-27 | 2016-01-06 | 百时美施贵宝公司 | As piperazine and the homopiperazine derivative of HIV adsorption inhibitor |
-
2017
- 2017-03-30 CN CN201710204729.4A patent/CN107028948B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN107028948A (en) | 2017-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kaštelan et al. | Diagnostic procedures and management of dry eye | |
| López-Plandolit et al. | Efficacy of plasma rich in growth factors for the treatment of dry eye | |
| Pisella et al. | Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study | |
| Rodrigues et al. | Vital dyes for chromovitrectomy | |
| Al-Saedi et al. | Dry eye disease: present challenges in the management and future trends | |
| US20080075787A1 (en) | Therapeutic Agent For Ophthalmic Diseases | |
| Valente et al. | Symptoms and signs of tear film dysfunction in glaucomatous patients | |
| Carracedo et al. | Evaluation of tear meniscus by optical coherence tomography after different sodium hyaluronate eyedrops instillation | |
| Ciancaglini et al. | An in vivo confocal microscopy and impression cytology analysis of preserved and unpreserved levobunolol-induced conjunctival changes | |
| Baffa et al. | Tear film and ocular surface alterations in chronic users of antiglaucoma medications | |
| Liu et al. | Therapeutic effects of sodium hyaluronate on ocular surface damage induced by benzalkonium chloride preserved anti-glaucoma medications | |
| Su et al. | Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study | |
| Hao et al. | Demodex folliculorum infestation in meibomian gland dysfunction related dry eye patients | |
| Schmid-Kubista et al. | Comparison of macular function and visual fields after membrane blue or infracyanine green staining in vitreoretinal surgery | |
| Srinivas et al. | Ocular surface staining: Current concepts and techniques | |
| Chang et al. | Clinical evaluation of the traditional Chinese prescription Chi‐Ju‐Di‐Huang‐Wan for Dry Eye | |
| Chaudhari et al. | Rodent models for dry eye syndrome: Standardization using benzalkonium chloride and scopolamine hydrobromide | |
| Kashiwagi et al. | Reduction in ocular hypotensive eyedrops by ab interno trabeculotomy improves not only ocular surface condition but also quality of vision | |
| US20070185014A1 (en) | Methods and compositions for modulating conjunctival goblet cells | |
| CN107028948B (en) | Purposes of the compound in the medicine for preparing treatment climacteric xerophthalmia | |
| Berhuni et al. | 20% Autologous serum vs. 0.05% cyclosporine and preservative-free artificial tears in the treatment of Sjögren related dry eye | |
| Tognetto et al. | The combination of trypan blue and brilliant blue G-assisted vitrectomy for macular pucker: histopathological findings | |
| Jeon et al. | Ocular surface changes after lateral rectus muscle recession | |
| Yaginuma et al. | Tear protein analysis in patients with primary acquired nasolacrimal duct obstruction treated with lacrimal passage intubation | |
| Berhuni et al. | Soro autólogo a 20% versus ciclosporina a 0, 05 e lubrificantes oculares sem conservantes no tratamento da síndrome do olho seco relacionada à Sjögren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Kong Shoufang Inventor after: Mao Yalin Inventor after: Yang Ling Inventor before: Bo Fenglei |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20171204 Address after: 266000 Shandong city of Qingdao province Chongqing District Road No. 81 Building No. 2 unit 201 Applicant after: Kong Shoufang Address before: Xiamen City, Fujian Province, 361005 South Siming Road No. 422, Xiamen University Applicant before: Bo Fenglei |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180109 Termination date: 20190330 |